Effects of different doses of recombinant human growth hormone on related factors in dwarfism children who were smaller for gestational age

  Objective  To investigate the effects of high-dose recombinant human growth hormone (rhGH) and low-dose rhGH on growth value of standard height deviation (△HtSDS), growth velocity (HV), serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) of dwarfism children who were smaller for gestational age (SGA).

  Methods  A total of 110 patients were selected as study subjects and were divided into two groups according to differed doses, with 55 cases per group. The patients in the low-dose group were given rhGH for 0.10~0.15 IU/kg daily, and those in the high-dose group were orally administrated rhGH for 0.16~0.20 IU/kg. The drug efficacy between the two groups was compared.

  Results  At 6, 12 and 24 months after treatment, the levels of △HtSDS, HV, blood IGF-1 and IGFBP-3 in the high dose group were higher than those in the low dose group (P < 0.05).

  Conclusion  High dose of rhGH has more obvious advantages in the treatment of SGA dwarfism children, and has more positive effects on HtSDS, HV, blood IGF-1 and IGFBP-3.